Tricida, Inc. (NASDAQ:TCDA) Director Sandra I. Coufal sold 5,000 shares of the firm’s stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $4.78, for a total transaction of $23,900.00. Following the sale, the director now owns 142,509 shares in the company, valued at approximately $681,193.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of TCDA opened at $4.92 on Friday. Tricida, Inc. has a twelve month low of $3.74 and a twelve month high of $28.18. The stock has a market capitalization of $247.34 million, a P/E ratio of -1.01 and a beta of 1.32. The company has a current ratio of 5.49, a quick ratio of 5.49 and a debt-to-equity ratio of 1.96. The company has a fifty day moving average price of $4.75.
Tricida (NASDAQ:TCDA) last issued its earnings results on Thursday, May 6th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.17). As a group, sell-side analysts forecast that Tricida, Inc. will post -3.08 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of TCDA. Morgan Stanley grew its stake in Tricida by 11,855.4% in the 4th quarter. Morgan Stanley now owns 4,541,994 shares of the company’s stock valued at $32,022,000 after acquiring an additional 4,504,003 shares during the period. Point72 Asset Management L.P. acquired a new stake in Tricida during the 1st quarter worth $14,042,000. Lion Point Capital LP acquired a new stake in Tricida during the 4th quarter worth $12,878,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Tricida during the 4th quarter worth $9,136,000. Finally, Opaleye Management Inc. purchased a new position in shares of Tricida during the 4th quarter worth $6,761,000. 65.76% of the stock is currently owned by institutional investors and hedge funds.
Tricida Company Profile
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.
Read More: History of the Euro STOXX 50 Index
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.